The Hellenic Association of Pharmaceutical Companies (SFEE) has announced that it has once again appealed to the Health Ministry in hopes of stopping a legislation that would make it more difficult for Greek patients to have access to new treatments and drugs.
Over the next few days, the Greek Parliament will be reviewing the legislation that says that any new drug must first receive a positive assessment via the Health Technology Assessment (HTA), which would mean serious delays in introducing the drugs to the Greek public awaiting treatments.
This is not the first time that the SFEE has addressed this issue, and just as recently as December, 2016, the organization wrote in a press release that these measures would “hamper the access of the seriously and chronically ill to innovative treatments, by delaying the launch of new and crucial medicinal products on the domestic market for up to four years,” explaining that “Such products can only be introduced in Greece if they are reimbursed in 14 EU countries (of which seven must participate in the voluntary health technology assessment (HTA) system). Four years of delay for patients whose only hope is access to an innovative treatment is tantamount to a sentence to a life of suffering or, worse yet, no life at all. Those patients do not have the luxury of time.”